Low-Dose Naltrexone (LDN)
Low-dose naltrexone (LDN) is naltrexone taken at very low doses. The dose is far below the standard dose for opioid or alcohol dependence. Naltrexone blocks opioid receptors (it is an opioid antagonist).
At low doses, the blockade lasts only a short time. The body responds by producing more of its own endorphins.
Researchers also think LDN may act on the immune system. It may change the function of macrophages, a type of immune cell.
That change may lower inflammatory signals such as TNF-alpha and IL-6. This pathway is not yet fully proven.
Clinical trials have tested this immune effect in chronic inflammatory conditions. These include multiple sclerosis and fibromyalgia.12
Some RRM clinicians consider LDN as an adjunct when one of three problems is suspected. The first is an immune response that prevents an embryo from implanting. The second is clinical endorphin deficiency. The third is immune dysfunction associated with endometriosis.
This use is off-label. Clinicians who consider LDN should review each patient's immune profile. They should also review her history of pregnancy and fertility.
Cited in this entry
- Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. https://pubmed.ncbi.nlm.nih.gov/20695007/
- Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. https://pubmed.ncbi.nlm.nih.gov/23359310/
This content is for educational purposes only and does not constitute medical advice. Consult an RRM clinician or healthcare provider for guidance specific to your situation.
